Document Detail


Potential role of recombinant human erythropoietin in the peri-surgical setting.
MedLine Citation:
PMID:  2182736     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
For patients participating in autologous blood programs, one factor influencing the likelihood of homologous blood exposure is the number of available autologous units. To study the role of human recombinant erythropoietin (rhEpo) in increasing the amount of autologous blood that can be obtained prior to surgery, we conducted a randomized double-blind controlled trial of rhEpo in 47 adult patients scheduled for elective orthopedic procedures. Patients received either rhEpo (600 U/kg) or placebo i.v. twice weekly over a 21-day study period, during which up to six units of blood were collected. Patients were deferred from donation for hematocrit less than 34%. All patients received FeSO4, 325 mg orally three times daily. The mean number of units collected was 5.4 +/- 0.2 and 4.1 +/- 0.2 (mean +/- SE) for the rhEpo and placebo patients, respectively. Mean red blood cell volume donated by rhEpo patients was 41% greater than placebo patients (961 ml vs. 683 ml, p less than 0.05) Only one of 23 patients (4%) treated with rhEpo were unable to donate greater than or equal to 4 U, compared to seven of 24 (29%) placebo patients. No adverse effects were attributed to rhEpo. We conclude that rhEpo is efficacious in increasing autologous blood donated in elective surgical patients.
Authors:
L T Goodnough
Related Documents :
18194386 - Mannose-binding lectin is involved in multiple organ dysfunction syndrome after cardiac...
11564086 - Vitamin e correlates inversely with non-transferrin-bound iron in sickle cell disease.
15155406 - Types of anaemic crises in paediatric patients with sickle cell anaemia seen in enugu, ...
1765296 - Relationship between peripheral vascular closure and proliferative retinopathy in sickl...
8203436 - Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with s...
3370096 - Evaluation of venous distension device: phase ii: cannulation of nonemergent patients.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of cell cloning     Volume:  8 Suppl 1     ISSN:  0737-1454     ISO Abbreviation:  Int. J. Cell Cloning     Publication Date:  1990 Jan 
Date Detail:
Created Date:  1990-05-21     Completed Date:  1990-05-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8308172     Medline TA:  Int J Cell Cloning     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  203-10     Citation Subset:  IM    
Affiliation:
Case Western Reserve University, Cleveland, Ohio 44106.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Blood Transfusion, Autologous*
Double-Blind Method
Erythrocyte Volume / drug effects*
Erythropoietin / pharmacology*
Evaluation Studies as Topic
Female
Humans
Male
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Recombinant Proteins / pharmacology
Grant Support
ID/Acronym/Agency:
01625//PHS HHS
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lymphopoiesis and IL-7.
Next Document:  Molecular modeling of human granulocyte-macrophage colony-stimulating factor.